Loading company…
Vertero Therapeutics, based in Woburn, develops gut microbiome small molecule therapies for conditions including autism.
Founded in 2016 and headquartered in Woburn, US, Vertero Therapeutics, Inc., formerly known as Axial Therapeutics, develops small molecule therapeutics that target the gut microbiome for conditions such as autism spectrum disorder, Parkinson's disease, liver disease and oncology. In October 2025, it raised USD 20 million in Series D funding from returning investors OneVentures and Seventure, with participation from unspecified investors. Its lead candidate, AB-2004, is aimed at irritability associated with autism.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in